Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies
Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.Peer-Reviewed Original ResearchConceptsPeak plasma concentrationPlasma concentrationsChronic basisDihydroperillic acidMean peak plasma concentrationLow-grade nauseaPerillyl alcoholStabilization of diseaseGastrointestinal side effectsH post ingestionPerillic acidMonoterpene perillyl alcoholStarting doseRefractory malignanciesPost ingestionSide effectsPatientsMajor metabolitePharmacokinetic studyDoseMicroMNauseaMalignancyAverage numberDisease